Results 91 - 100 of 2296
[REPORT SUMMARY] Periodic Report Summary 2 - STOPENTERICS (Vaccination against Shigella and ETEC: Novel antigens, novel approaches)
Project context and objectives:
STOPENTERICS aims at developing novel vaccine candidates against shigella and escherichia coli (ETEC) for children of the developing world. This consortium gathers a unique combination of laboratories, platforms, vaccinology centers from acad...
Programme: FP7-HEALTH
Record Number: 56779
Last updated on: 2013-06-12
[REPORT SUMMARY] Periodic Report Summary 5 - STOPENTERICS (Vaccination against Shigella and ETEC: novel antigens, novel approaches)
STOPENTERICS aims at developing novel vaccine candidates against Shigella and ETEC for children of the developing world. This consortium gathers a unique combination of laboratories, platforms, vaccinology centers from academia and industry in...
Programme: FP7-HEALTH
Record Number: 182434
Last updated on: 2016-05-20
[REPORT SUMMARY] Periodic Report Summary 4 - STOPENTERICS (Vaccination against Shigella and ETEC: novel antigens, novel approaches)
STOPENTERICS aims at developing novel vaccine candidates against Shigella and ETEC for children of the developing world. This consortium gathers a unique combination of laboratories, platforms, vaccinology centers from academia and industry in...
Programme: FP7-HEALTH
Record Number: 168302
Last updated on: 2015-07-21
[PROJECT] ACADEMIC GMP - The impact of Regulation (EC) No 1394/2007 on the development of Advanced Therapy Medicinal Products (ATMPs): an academic perspective
ID: 260773
Start date: 2010-09-01, End date: 2013-05-31
Advanced Therapy Medicinal Products (ATMPs) are medicinal products for human use, based on gene therapy, somatic cell therapy or tissue engineering. A rapidly growing area in translational research, they represent the ‘next generation’ of complex medicines for complex disease...
Programme: FP7-HEALTH
Record Number: 96783
Last updated on: 2017-07-02
Advanced Therapy Medicinal Products are gene therapy, somatic cell therapy or tissue engineered products. Regulation (EC) 1394/2007 has defined ATMPs to be drugs; at the gap between medicinal products and medical devices, these complex medicines promise...
Programme: FP7-HEALTH
Record Number: 140442
Last updated on: 2014-08-01
[RESULT IN BRIEF] Arzneimittel der nächsten Generation
Technologische Fortschritte in der Biologie und translationalen Forschung haben eine neue Ära therapeutischer Möglichkeiten eingeleitet. Da die meisten Ansätze in akademischen bzw. Forschungseinrichtungen entwickelt werden, hat die EU vor allem die Aufgabe, GMP- (gute Herstellungspraxis) und Gesundheitsstandards zu gewährleisten.
Programme: FP7-HEALTH
Record Number: 90287
Last updated on: 2013-01-28
[RESULT IN BRIEF] Medicamentos de nueva generación
Los avances tecnológicos en el campo de la biología y la investigación transnacional han dado lugar a una nueva era en las modalidades terapéuticas. La mayoría de estos planteamientos se diseña y desarrollan en institutos académicos y, por tanto, la Unión Europea ha de garantizar el cumplimiento de las normas sanitarias relacionadas con las buenas prácticas de fabricación (GMP).
Programme: FP7-HEALTH
Record Number: 90287
Last updated on: 2013-01-28
[RESULT IN BRIEF] Medicine di prossima generazione
I progressi tecnologici nel settore della biologia e della ricerca traslazionale hanno portato a una nuova era di modalità terapeutiche. Poiché la maggior parte di questi approcci sono progettati e sviluppati in istituzioni accademiche, l'UE deve assicurare che gli standard sanitari relativi alle norme di buona fabbricazione (GMP) siano rispettati.
Programme: FP7-HEALTH
Record Number: 90287
Last updated on: 2013-01-28
[RESULT IN BRIEF] Des médicaments de prochaine génération
Les défis technologiques dans le domaine de la biologie et de la recherche translationnelle ont engendré une nouvelle ère de modalités thérapeutiques. Étant donné que ces approches sont conçues et développées dans les institutions académiques, l'UE a besoin d'assurer que les normes de santé des bonnes pratiques de fabrication (BPF) sont maintenues.
Programme: FP7-HEALTH
Record Number: 90287
Last updated on: 2013-01-28
[RESULT IN BRIEF] Next-generation medicines
Technological advances in the field of biology and translational research have led to a new era of therapeutic modalities. As most of these approaches are designed and developed in academic institutes, the EU needs to ensure that good manufacturing practice (GMP) health standards are maintained.
Programme: FP7-HEALTH
Record Number: 90287
Last updated on: 2013-01-28
List retrieved on: 2017-08-02
